News
FDA Grants De Novo Classification to neuropacs™, a First-in-Class AI-Based MRI Diagnostic Aid for Parkinsonian Syndromes
Multicenter Clinical Evidence Supports Use of neuropacs™ to Assist Clinicians in Differentiating Parkinsonian Syndromes, Strengthening Commercial Momentum
Neuropacs Announces the Publication of a New Study Comparing the First‑of‑Its‑Kind FDA De Novo–Classified Imaging Biomarker for Parkinson’s Disease with CSF Alpha‑Synuclein Seed Amplification Assay
Publication of a Breakthrough Study Demonstrating AI‑Enabled Diffusion MRI Can Accurately Differentiate Alzheimer’s Disease Dementia and Dementia with Lewy Bodies
JAMA Neurology publishes landmark study showing neuropacs™ AI technology significantly enhances the diagnostic accuracy of Parkinson’s disease and atypical parkinsonism
Neuropacs Closes Seed Round of Financing. Secures over $1.0M in Early-Stage Funding
Automated Imaging Diagnostics Awarded Phase II Grant for Clinical Performance Testing of neuropacs™ in Parkinsonism Diagnosis
Revolutionary Alzheimer’s Diagnostic Technology Option Agreement Secured by neuropacs in Collaboration with UF
Ready to improve your outcomes using our precision AI platform?
Our dedicated team can help you determine which neuropacs™ solution best fits your clinical or research needs.